Toprol XL patient counseling information: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{Metoprolol}} | {{Metoprolol}} | ||
{{CMG}} | {{CMG}} | ||
Advise patients to take TOPROL-XL regularly and continuously, as directed, preferably with or immediately following meals. If a dose is missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue TOPROL-XL without consulting the physician. | Advise patients to take TOPROL-XL regularly and continuously, as directed, preferably with or immediately following meals. If a dose is missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue TOPROL-XL without consulting the physician. |
Revision as of 08:42, 13 March 2014
Clinical data | |
---|---|
Trade names | Lopressor, Toprol-xl |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682864 |
[[Regulation of therapeutic goods |Template:Engvar data]] |
|
Pregnancy category | |
Routes of administration | Oral, IV |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 12% |
Metabolism | Hepatic via CYP2D6, CYP3A4 |
Elimination half-life | 3-7 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H25NO3 |
Molar mass | 267.364 g/mol |
3D model (JSmol) | |
Melting point | 120 °C (248 °F) |
| |
| |
(verify) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Advise patients to take TOPROL-XL regularly and continuously, as directed, preferably with or immediately following meals. If a dose is missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue TOPROL-XL without consulting the physician.
Advise patients (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient’s response to therapy with TOPROL-XL has been determined; (2) to contact the physician if any difficulty in breathing occurs; (3) to inform the physician or dentist before any type of surgery that he or she is taking TOPROL-XL.
Heart failure patients should be advised to consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.
TOPROL-XL and PLENDIL are trademarks of the AstraZeneca group of companies.[1]
References
Adapted from the FDA Package Insert.
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles with non-default infobox title
- Beta blockers
- Cardiovascular Drugs
- Drugs